Sentences with phrase «t cell tumor»

Not exact matches

The latter «really just had quiescent T - cells in their tumors,» says Wargo.

• Tessa Therapeutics, a Singapore - based biopharmaceutical company focusing on T cell therapy for solid tumors, raised $ 80 million in funding.

The favorable composition of flora were associated with a «higher activation status» of their killer T cells within the tumor compared to those who had an abundance of Bacteroidales.

The institute, which includes over 40 laboratories and more than 300 researchers, said the research would focus on modifying a patient's own immune system T - cells to target a tumor, studying ways to boost patient response to current immunotherapy drugs.

CAR - T cell therapy is a form of immunotherapy, a rapidly developing cancer treatment that uses patients» own immune cells to attack tumors.

His work indicates that this cell surface marker could serve as a target for a novel brain cancer vaccine or T - cell therapies engineered to recognize and kill tumors carrying that neoantigen.

These CAR - T cells were able to penetrate the blood - brain barrier, one of the major hurdles in treating brain tumors.

By comparing the results to cells from paired normal tissue, researchers get a detailed molecular picture of the tumor environment, including the types and activity levels of T cells that are critical to the immunotherapy response.

Different CARs determine what types of tumors T cells target.

Tumors (red) can use PD - 1 proteins (yellow, orange) to lock onto T cells (white) and shut them down.

Furthermore, while the approach has shown tremendous promise in treating blood - based cancers like leukemia, solid tumors remain stubbornly difficult to treat with CAR T cells.

Even before treatment, cancer patients in the study had a small number of infection - and tumor - fighting T cells that target these unusual proteins, the researchers found.

«Combination therapy strengthens T cells in melanoma pre-clinical study: Findings have implications for treating tumors lacking tumor suppressor gene PTEN.»

A pre-clinical study of two drugs designed to boost T cell performance, has revealed the agents, when give in combination, may enhance the immune system's ability to kill melanoma tumors deficient in the tumor suppressor gene PTEN.

They then tried adoptive T cell therapy (ACT), in which T cells directed against a tumor are infused into a patient.

When the dendritic cells are activated, they train T cells — their allies in the adaptive arm of the immune system — to attack cancer cells anywhere in the body, whether at the site of the original tumor or distant metastases.

«To my great surprise, even injecting 10 million activated T cells specific to the P1A antigen did not affect tumor growth in this induced tumor model,» says Van den Eynde.

Since the cancer cells in both types of tumors were the same, the researchers compared the noncancerous cells present in the induced and transplanted tumors to explore what might be causing the T cell apoptosis.

«This combinational treatment also was well tolerated and enhanced the number of CD8 T cells at the tumor site.

The immune system depends on molecules called T cell receptors on the surface of T cells to recognize and respond to foreign antigens from virus - infected cells, tumors and other threats.

«This explained why they did not persist: The induced tumor behaves like a sink for these T cells.

These results suggest GSK2636771 treatment can «synergize» with OX40 agonist antibodies to augment effector functions of tumor - reactive T cells.»

Their paper, which appears in Nature Communications, describes how an immune cell recruited to the tumor induces the programmed suicide, or apoptosis, of the killer T cells harnessed by many immunotherapies.

In effect, PD - 1 may actually help to preserve a «reserve force» of T cells that can fight on later in the long - term cellular war between the immune system and foreign invaders or tumors.

They inhibit the abilities of tumor - infiltrating white blood cells and increase the abilities of immunosuppressive regulatory T cells.

Seven to eight weeks after the tumor was established, each mouse received one intravenous injection of GD2 CAR - T cells or, as a control treatment, an injection of CAR - T cells that react to a different target.

We designed chimeric antigen receptor (CAR) T cells that specifically target podoplanin (PDPN), a key protein for the progression of solid tumors, including GBM.»

To begin the research, the scientists screened human DIPG tumor cultures for surface molecules that could act as targets for CAR - T cells.

«We gave CAR - T cells intravenously, and they tracked to the brain and cleared the tumor.

In the mice that received GD2 CAR - T cells, the DIPG tumors were undetectable after 14 days, while mice receiving the control treatment had no tumor regression.

Using immunostaining, the researchers counted the remaining tumor cells; the mice treated with GD2 CAR - T cells had a few dozen remaining cancer cells per animal, while each control mouse had tens of thousands of cancer cells.

Next, the team tested the GD2 CAR - T cells in mice whose brainstem was implanted with human DIPG tumors, an experimental system that Monje's lab pioneered.

There is currently a PD - 1 antibody on the market that blocks T cell exhaustion in patients with solid tumors, like lung cancer and melanoma.

Spinal cord tumors were effectively cleared by the GD2 CAR - T cells.

One advantage of this method is that it only activates a certain type of immune cell, the dendritic cell or T - cell, and only in one part of the body, near the draining lymph nodes or tumor, which helps cut down on the system - wide side effects often seen with chemotherapy.

«Considering that PDPN is associated with poor prognosis in GBM, CAR T - cell therapy that targets this protein is promising for treatment of patients with relapsed or resistant tumors following first - line chemotherapy,» says Toshihiko Wakabayashi, a coauthor and the chair of Department of Neurosurgery Nagoya University School of Medicine.

The report is believed to be the first to suggest that regulatory T cells are subject to the functional exhaustion that also plagues conventional T cells that fight infectious agents and tumor cells.

OX40 functions as a throttle for T cells, another type of immune cell crucial for battling tumors, and the anti-OX40 antibodies rev up these cells.

You have T cells for the rest of your life, so if the tumor reoccurs those T cells can mobilize themselves again against the tumor.

By blocking CTLA - 4, Allison found he could unleash the T cells to combat tumors.

By masking checkpoint receptors, Yervoy and Opdivo expand the number of circulating, tumor - recognizing T cells.

Those candidates include antibodies that would activate and arm more T cells and bispecific, engineered antibodies that physically bring T cells to the tumor cells they are armed to kill.

T cells genetically engineered to make the chimeric antigen receptor can recognize and target tumor cells.

Although changes in treatment methodology still have to be studied, Dr. Cripe believes it may be that the timing of various treatments is what matters, and that perhaps initially suppressing immunity could allow the virus to infect a large number of tumor cells before relieving the immunosuppression to allow the body's own T cells to fight off the tumor.

«We're still trying to figure out why these anti-tumor T - cells don't go into pancreatic tumors like they do for other malignancies,» Beatty said.

The vaccine harnesses the natural process of T - cell immunity to tumors, but enhances it to help overcome tumors» formidable defenses.

In principle, an attack by such T - cells on tumors should be particularly powerful as well as highly tumor - specific and thus sparing of healthy cells.

Half of the patients that could be evaluated showed big increases in the numbers of T - cells specifically reactive to tumor material, indicating a good response to vaccination.

When the cells are reinfused, they stimulate T cells to attack the patient's tumors.

In pancreatic cancer, their activity boosts tumor growth and spread, and may also help suppress T cells and other immune elements that would otherwise attack the tumor.